Neuren Pharmaceuticals Limited

ASX:NEU 주식 보고서

시가총액: AU$1.6b

Neuren Pharmaceuticals 관리

관리 기준 확인 3/4

Neuren Pharmaceuticals CEO는 Jon Pilcher, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 A$ 1.36M, 40.2% 로 구성됩니다. 40.2% 급여 및 59.8% 보너스(회사 주식 및 옵션 포함). 는 A$ 4.92M 가치에 해당하는 회사 주식의 0.31% 직접 소유합니다. 4.92M. 경영진과 이사회의 평균 재임 기간은 각각 4.4 년과 6.3 년입니다.

주요 정보

Jon Pilcher

최고 경영자

AU$1.4m

총 보상

CEO 급여 비율40.2%
CEO 임기4.5yrs
CEO 소유권0.3%
경영진 평균 재임 기간4.4yrs
이사회 평균 재임 기간6.3yrs

최근 관리 업데이트

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

CEO 보상 분석

Jon Pilcher 의 보수는 Neuren Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

AU$117m

Mar 31 2024n/an/a

AU$137m

Dec 31 2023AU$1mAU$549k

AU$157m

Sep 30 2023n/an/a

AU$106m

Jun 30 2023n/an/a

AU$55m

Mar 31 2023n/an/a

AU$28m

Dec 31 2022AU$546kAU$396k

AU$184k

Sep 30 2022n/an/a

-AU$3m

Jun 30 2022n/an/a

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021AU$432kAU$203k

-AU$8m

보상 대 시장: Jon 의 총 보상 ($USD 886.67K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.10M ).

보상과 수익: Jon 의 보상은 지난 1년 동안 20% 이상 증가했습니다.


CEO

Jon Pilcher

4.5yrs

테뉴어

AU$1,364,404

보상

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...


리더십 팀

이름위치테뉴어보상소유권
Jonathan Pilcher
CEO, MD & Executive Director4.5yrsAU$1.36m0.31%
A$ 4.9m
Lauren Frazer
CFO & Company Secretary4.3yrs데이터 없음데이터 없음
Lawrence Glass
Chief Science Officer20.8yrs데이터 없음데이터 없음
Gerry Zhao
Vice President of Corporate Developmentno data데이터 없음데이터 없음
Liza Squires
Chief Medical Officer2.3yrs데이터 없음데이터 없음

4.4yrs

평균 재임 기간

경험이 풍부한 관리: NEU 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Jonathan Pilcher
CEO, MD & Executive Director3.4yrsAU$1.36m0.31%
A$ 4.9m
Dianne Angus
Independent Non-Executive Director6.3yrsAU$75.00k0.023%
A$ 370.8k
Jenny Harry
Independent Non-Executive Director6.3yrsAU$75.00k0.023%
A$ 366.7k
Patrick Donald Davies
Independent Non-Executive Chairman6.3yrsAU$125.00k0.21%
A$ 3.3m
Joe Basile
Independent Non-Executive Director1.7yrsAU$62.50k0.017%
A$ 264.6k

6.3yrs

평균 재임 기간

경험이 풍부한 이사회: NEU 의 이사회경험(평균 재직 기간 6.3 년)으로 간주됩니다.